FDA Warns that Vancomycin Eye Injections May Lead to Blindness

October 6, 2017: By Joan McKenna

1 Ophthalmic NewsVancomycin injections during eye surgery can lead to hemorrhagic occlusive retinal vasculitis (HORV), a rare, potentially blinding postoperative complication, the FDA warned Oct. 3 in a compounding risk alert to health care providers.

The agency said it received an adverse event report Aug. 14, 2017, for a patient who developed bilateral HORV after being administered injections of a compounded triamcinolone, moxifloxacin, and vancomycin (TMV) formulation in each eye at the conclusion of cataract surgeries performed two weeks apart. The TMV formulation was compounded by Imprimis Pharmaceuticals at its outsourcing facility in Ledgewood, New Jersey.

The FDA said symptoms of HORV include a delayed onset of sudden painless decreased vision, intraocular inflammation, intraretinal hemorrhage, retinal vasculitis, vascular occlusion, and retinal ischemia.

At the 2016 AAO meeting, Dean Eliott, MD, said HORV is suspected to be a rare type III hypersensitivity to vancomycin, but its exact cause and pathogenesis remain unproven.

The FDA said many ophthalmologists use intraocular vancomycin during cataract surgery to prevent postoperative endophthalmitis.

The agency said there is no US-approved vancomycin formulation for intraocular injection, and it is unaware of any adequately controlled studies demonstrating the safety and efficacy of vancomycin in preventing endophthalmitis.

The formulation is usually prepared at the surgical site or obtained in advance of surgery from a compounding pharmacy.

The agency concluded that prophylactic use of vancomycin, alone or in a compounded combination drugs, during cataract surgery is generally not recommended due to the risk of HORV.

The FDA said that, if vancomycin is administered to both eyes, patients with HORV likely will wind up legally blind.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023